ProPhase Labs, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Transactions Affecting Stockholders' Equity (Details Textual)

Transactions Affecting Stockholders' Equity (Details Textual) (USD $)	3 Months Ended		1 Months Ended		7 Months Ended
	Mar. 31, 2015	Mar. 31, 2014	Nov. 21, 2012	May 28, 2014	Dec. 31, 2014
Stockholders' Equity [Line Items]
Equity Method Investment Ownership Percentage Required For Rights Exercisable Under Right Agreement	15.00%
Common Stock, Shares, Issued	25,125,113us-gaap_CommonStockSharesIssued				25,125,113us-gaap_CommonStockSharesIssued
Proceeds From Issuance Of Common Stock	$ 0	$ 947,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 45
Cash Less Exercise Of Right Terms	In the event of a cashless exercise of the Right and the acquirer has acquired less than 50% beneficial ownership of the Company
Share Based Compensation Arrangement By Share Based Payment Option Expiration Terms	No incentive stock option could be exercisable more than ten years after the date of grant or five years after the date of grant where the individual owns more than ten percent of the total combined voting power of all classes of stock. Stockholders approved the 1997 Plan in Fiscal 1998
Percentage Of Discount On Exercise Of Right	50.00%
2012 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Maximum Number Of Common Stock Authorized For Issuance Over 36 Months			2,500,000
2014 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Maximum Number Of Common Stock Authorized For Issuance Over 36 Months				3,000,000
Investor Right To Use Excess Proceeds, Maximum Percentage	5.00%
Share Purchase Put Restrictions Maximum Percentage Of Ownership Held By Investor To Purchase Shares In Equity Line Of Credit	4.99%
Common Stock, Capital Shares Reserved for Future Issuance	438,480			3,000,000
Equity Line, Purchase Price Percentage	95.00%
Common Stock, Shares, Issued					2,561,520
Proceeds From Issuance Of Common Stock					3,700,000
Agreement Term				36 months
Purchase Price Value	500,000
Common Stock, Capital Shares Reserved For Future Issuance	438,480			3,000,000
Ted Karkus [Member]
Stockholders' Equity [Line Items]
Equity Method Investment, Ownership Percentage	20.00%
Plan 1997 [Member]
Stockholders' Equity [Line Items]
Options outstanding - Shares	26,500
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Common Stock Shares Unissued	2,500,000
Available for grant, Shares (in shares)	900,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period	1,481,750
Plan 2010 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	1,600,000
Share Based Compensation Arrangement By Share Based Payment Award, Options, Deemed Cancelled	581,750
Available for grant, Shares (in shares)	19,659
Directors Plan 2010 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized	425,000
Available for grant, Shares (in shares)	147,808
Amended Option Plan 1997 [Member]
Stockholders' Equity [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	4,500,000
Common Stock [Member] \| Dutchess [Member] \| 2012 Equity Line of Credit [Member]
Stockholders' Equity [Line Items]
Stock Issued During Period Shares Under Specific Agreement	698,207
Stock Issued During Period Value Specific Agreement	$ 1,200,000